American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 1(64), 2019
DOI: 10.1128/aac.01839-19
Full text: Unavailable
The increasing global prevalence of carbapenem-resistant Enterobacteriaceae (CRE) combined with the decline in effective therapies is a public health care crisis. After respiratory tract infections, urinary tract infections and associated urosepsis are the second most affected by CRE pathogens.